Progress towards a vaccine for schistosomiasis

Abstract

Schistosomiasis continues to be a significant health problem, especially in Africa. While the recent World Health Assembly resolution to apply mass drug treatment of school age children in endemic areas is a very promising development, a preferable long-term solution would be provided by a protective vaccine. Encouragingly, one vaccine, Bilhvax, is in phase II trials. However, there is a danger that momentum towards the goal of developing a vaccine against schistosomiasis is dissipating. This article reviews the current situation in this important area of schistosomiasis research.